The purpose of this study is to demonstrate that the new yellow fever vaccine is as safe and effective as the currently licensed yellow fever vaccines.
Eligibility criteria include: age 18–59 inclusive, not pregnant or breastfeeding, no history of prior flavivirus infection or vaccination, no history of immune compromise, no history of thymic disease orthymectomy.
Study requirements: one vaccination visit, 9–10 follow-up visits over five years, blood sampling, symptom diary.
Compensation: $870–$950 depending on visits completed.
To obtain more information, contact the Center for Immunization Research recruitment department at 410-955-7283 or visit the CIR website.
PI: Kawsar Talaat